Latham & Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, announced the closing of an upsized underwritten public offering of shares of its common stock at a price to the public of US$17 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately US$345 million. All shares in the offering were sold by Alumis.

Latham & Watkins LLP represented the underwriters in the transaction with a Capital Markets team led by Orange County/Bay Area partners Shayne Kennedy and Ross McAloon, with associates Jacob Walsh, Kennedy Holmes, Lexi Zintel, and Brock Meyer. Advice was also provided on healthcare matters by Bay Area partner Betty Pang; on FDA matters by Washington, D.C. counsel Chad Jennings, with associate Evan Miller; on executive compensation and benefits matters by Los Angeles/Orange County partner Michelle L.C. Carpenter and Orange County counsel Sara Schlau, with associate Julie Voorhes; on tax matters by Los Angeles partner Eric Cho, with associate Joseph Marcus; on intellectual property matters by San Diego/Bay Area partner Christopher Hazuka and San Diego counsel Robert Yeh, with associate Dylan O'Connor; and on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Chad Leiper.